Policymakers often talk about protecting patients against the predatory practices of insurers and PBMs. It is about time for state and federal legislators to support such legislations to ensure that ONLY patients benefit from such patient assistance programs and to stop PBM and insurers from profiteering on the backs of patients.
Dr. Robert Popovian
Drs. Robert Popovian (a member of the Scientific Advisory Board at ACSH) and Radife Kiral, both at Pfizer, examine the response of our healthcare system to the COVID pandemic. In some areas we did well; in others not so well. What can we do better in the future?
The FDA needs to step up and fix the definition of strength. "Business as usual” under the existing language of the Biologics Price Competition and Innovation Act of 2009 means continued disincentives to promote a more aggressive uptake of biosimilars.
By any measure, today's announcement about the unexpected efficacy of the Pfizer/BioNTech coronavirus vaccine is great news. But, Pfizer's Dr. Robert Popovian cautions us that the job is not done. There are policies that are essential to ensure the vaccine is promoted to the public, distributed, and administered properly. And be priced so that everyone can get it. Devil. Details.